Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.52 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736751 | 0.92 | ALOX15 (0.52) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL18262923 | 0.85 | LMNA (0.53) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL16117670 | 0.79 | ALDH1A1 (0.67) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL15631282 | 0.79 | LMNA (0.54) | ALOX15ALDH1A1CYP1A2MAPTLMNA | |
| SCHEMBL11865828 | 0.78 | ALOX15 (0.62) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL10937876 | 0.78 | ALOX15 (0.54) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL12393857 | 0.78 | ALOX15 (0.65) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL8209720 | 0.78 | ALOX15 (0.58) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL4126691 | 0.77 | ALOX15 (0.64) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 | |
| SCHEMBL9503098 | 0.77 | ALDH1A1 (0.71) | ALOX15ALDH1A1SMN1; SMN2KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926267-B2 | Covalent inhibitors of K-Ras G12C | ARAXES PHARMA LLC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALOX15 4571/4885ALDH1A1 2706/4885SMN1; SMN2 3761/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALOX15 4571/4885ALDH1A1 2706/4885SMN1; SMN2 3761/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ALOX15 4571/4885ALDH1A1 2706/4885SMN1; SMN2 3761/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | ALOX15 4571/4885ALDH1A1 2706/4885SMN1; SMN2 3761/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | ALOX15 4380/4885ALDH1A1 1577/4885SMN1; SMN2 3583/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | ALOX15 4571/4885ALDH1A1 2706/4885SMN1; SMN2 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.